the short version
- Workers on GLP-1 medications in Denmark took 17 % fewer long-term sick-leave spells than comparable peers.
- The reduction translates to salary savings of up to 1.5 % per employee, roughly $866 on average.
- The analysis used Denmark’s linked worker-level and medication-usage data and was released this month by the National Bureau of Economic Research.
what happened
A new economic study released through the National Bureau of Economic Research examined Danish records that combined employment data with prescription information for GLP-1 drugs. Researchers found that patients who received a GLP-1 medication took 17 % less long-term sick leave, defined as absences lasting more than 30 days, compared with workers who did not use the drugs. The authors highlighted the potential monetary impact, noting up to a 1.5 % cut in individual salary costs, which averages to about $866 per worker.
plain-language background
GLP-1 drugs belong to a class called glucagon-like peptide-1 receptor agonists. They are prescribed to treat type 2 diabetes and obesity.
how it works (and what’s at stake)
The drugs act on the body’s GLP-1 pathways, improving blood-sugar control and promoting a feeling of fullness, which often leads to weight loss and better cardiovascular health. Think of the pathway as a valve that throttles appetite and glucose spikes, keeping the system from overloading. When health improves, employees are less likely to need prolonged recovery time, which directly cuts the length of sick-leave spells.
why it matters
- Workers using GLP-1 therapy could see personal salary savings, estimated at $866 each, because fewer long-term absences mean less time without full pay.
- Employers benefit from a reduction in the number of extended leaves, easing the burden of paying salaries for long-term absence periods.
- Governments stand to save on the state-funded component of sick leave, since fewer employees qualify for the > 30-day support.
- The 17 % drop observed in Denmark suggests that, if similar patterns appear elsewhere, productivity gains could be sizable across a workforce that includes many individuals with diabetes or obesity.
the numbers behind the analysis
| Metric | Finding | Context |
|---|---|---|
| Reduction in long-term sick leave | 17 % lower utilization | Compared with non-users |
| Salary savings per worker | Up to 1.5 % of salary (about $866) | Average estimate |
how much to make of it
The study’s conclusions rely on Danish data only, where the split between employer-paid short-term and state-paid long-term leave differs from most other countries. The analysis does not include the price of the GLP-1 medicines themselves, so the net financial balance remains uncertain. Moreover, the outcome measured was only long-term sick leave; short-term absences and presenteeism (working while ill) were not directly quantified. These limitations mean the reported $866 savings per worker should be viewed as a partial picture of the overall economic impact.
what happens next
The authors suggest the findings could be relevant to the U.S. labor market, which lacks the same generous sick-leave provisions. However, no U.S.-specific data are available yet. Future research may need to:
- Replicate the analysis in other countries with different sick-leave structures.
- Examine short-term absenteeism and presenteeism to capture the full productivity picture.
- Incorporate drug acquisition costs to assess the complete cost-benefit equation.
Until such data emerge, policymakers and employers will likely weigh the study’s insights against local wage-cost structures and existing sick-leave policies.
Sources
- CBS News, “GLP-1 drugs linked to 17 % drop in worker sick-leave, new economic study finds” (https://www.cbsnews.com/news/glp1-drugs-worker-sick-leave-study/)
- WDBO, “GLP-1 drugs linked to 17 % drop in worker sick leave, new economic study finds” (https://www.wdbo.com/news/local/glp-1-drugs-linked-17-drop-worker-sick-leave-new-economic-study-finds/U6MBOQOJERH4DJ7QJKSINTMSTE/)
Related Coverage
- The GLP-1 Nutrition Gap: Why Meal Replacement Shortcuts May Undermine Weight Loss Success
- Novo Nordisk files lawsuit accusing Eli Lilly of deceptive GLP-1 advertising
- PROTECT-Cog: The $100 Million Global Effort to Combine Lifestyle and Metabolic Therapy for Dementia Prevention
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.